<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2025-12-17</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2025-12-17</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>72</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>2</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
ADAM12è¢«é‰´å®šä¸ºé˜»ç¢è‚¿ç˜¤å…ç–«çš„å…³é”®æ€§æˆçº¤ç»´ç»†èƒæ£€æŸ¥ç‚¹ï¼›EWSR1::ETSç™ŒåŸºå› é€šè¿‡è°ƒæ§æ ¸å¿ƒè°ƒæ§ç¯è·¯æœºåˆ¶åœ¨å°¤æ–‡æ°è‚‰ç˜¤ä¸­å‘æŒ¥ä¸»å¯¼ä½œç”¨ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è‚ é“é»è†œå…ç–«ï¼šç ”ç©¶PKM2/STAT1é€šè·¯åœ¨Peyer'sé›†åˆæ·‹å·´ç»“ä¸­å¯¹å¹¼ç¨šBç»†èƒå‘½è¿çš„å½±å“ã€‚<br />
- è‚¿ç˜¤å…ç–«ï¼šæ¢ç©¶ADAM12åœ¨ä¸åŒè‚¿ç˜¤æ¨¡å‹ä¸­ä½œä¸ºæˆçº¤ç»´ç»†èƒæ£€æŸ¥ç‚¹é˜»ç¢æŠ—è‚¿ç˜¤å…ç–«çš„æœºåˆ¶ã€‚<br />
- å°¤æ–‡æ°è‚‰ç˜¤ï¼šè§£æEWSR1::ETSç™ŒåŸºå› å¦‚ä½•é‡å¡‘å…¶æ ¸å¿ƒè°ƒæ§ç¯è·¯ã€‚<br />
- è„‚è´¨æ°§åŒ–è‡ªç”±åŸºé˜²å¾¡ï¼šæ­ç¤ºäº†å…¶ä¿¡å·é€šè·¯å’Œè¡¨è§‚é—ä¼ è°ƒæ§æœºåˆ¶ã€‚<br />
- m6Aè¡¨è§‚è½¬å½•ç»„ç¼–è¾‘ï¼šç­›é€‰å¹¶é‰´å®šç™Œç—‡ä¸­çš„åŠŸèƒ½æ€§m6Aä½ç‚¹ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- å•ç»†èƒæµ‹åºï¼ˆscRNA-seqï¼‰æŠ€æœ¯åœ¨è‚¿ç˜¤å…ç–«å’Œç¥ç»ç§‘å­¦ä¸­çš„å¹¿æ³›åº”ç”¨ã€‚<br />
- Connectome-seqï¼šå®ç°å•çªè§¦åˆ†è¾¨ç‡ç¥ç»å…ƒè¿æ¥å›¾è°±ç»˜åˆ¶ã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
ç ”ç©¶äººå‘˜å› åœ¨åŸºå› ç»„ä¸RNAæµ‹åºæŠ€æœ¯ä¸Šçš„çªç ´æ€§åº”ç”¨ï¼Œæ˜¾è‘—æå‡äº†ç½•è§ç—…è¯Šæ–­èƒ½åŠ›ï¼›åŒæ—¶ï¼Œå¤§éº»åŒ–åˆç‰©ï¼ˆCBDä¸THCï¼‰å¯¹åµå·¢ç™Œç»†èƒå±•ç°å‡ºå¼ºæ•ˆæŠ‘åˆ¶ä½œç”¨ï¼Œä¸ºç™Œç—‡æ²»ç–—å¸¦æ¥æ–°å¸Œæœ›ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- åˆ©ç”¨RNAæµ‹åºä¸å› æœå»ºæ¨¡ï¼Œè§£æåŸºå› é€šè·¯ä¸äººç±»æ€§çŠ¶çš„è”ç³»ã€‚<br />
- æ¢ç´¢å¤§éº»åŒ–åˆç‰©ï¼ˆCBDã€THCï¼‰åœ¨æŠ‘åˆ¶åµå·¢ç™Œç»†èƒç”Ÿé•¿å’Œè½¬ç§»ä¸­çš„æ½œåŠ›ã€‚<br />
- è¯„ä¼°ç„¦è™‘å’Œå¤±çœ å¯¹å…ç–«ç»†èƒï¼ˆç‰¹åˆ«æ˜¯è‡ªç„¶æ€ä¼¤ç»†èƒï¼‰æ•°é‡çš„å½±å“ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- æ•´åˆåŸºå› æ•ˆåº”å¤§å°ä¸RNAæµ‹åºæ‰°åŠ¨æ•°æ®ï¼Œæ„å»ºåŸºå› è‡³ç»†èƒç¨‹åºåŠäººç±»æ€§çŠ¶çš„å› æœé€šè·¯å›¾ã€‚<br />
- å‘ç°CBDä¸THCè”åˆä½¿ç”¨èƒ½æœ‰æ•ˆå‡ç¼“åµå·¢ç™Œç»†èƒç”Ÿé•¿å’Œé›†è½å½¢æˆã€‚</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (68æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE285427 PKM2/STAT1é€šè·¯è°ƒæ§æ´¾æ°æ·‹å·´é›†ç»“å†…ç”Ÿå‘ä¸­å¿ƒå½¢æˆä¸­å¹¼ç¨šBç»†èƒçš„å‘½è¿ä»¥åŠè‚ é“é»è†œå…ç–«</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmunityã€B cellã€pathwayã€gutã€regex:gut(-?microbiome)?<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Li Zeng ; Zhiyin HuangSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThis study investigates the effects of high-protein diets on intestinal B cell development and their role in Crohnâ€™s disease (CD) pathogenesis. Our results demonstrate that a high-protein diet (HPD) combined with low-dose dextran sulfate sodium (DSS) effectively models CD in juvenile mice, leading to disrupted B cell development in Peyerâ€™s patches (PPs). This is characterized by a reduction in germinal center (GC) B cells and an increase in plasma cells in PPs, accompanied by downregulation of the PKM2/STAT1 signaling pathway in B cells, as validated through single-cell RNA sequencing (scRNA-seq), BCR sequencing (scBCR-seq) and flow cytometry.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285427" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>GSE313761 å•ç»†èƒç­›é€‰é‰´å®šå‡º ADAM12 ä¸ºæˆçº¤ç»´ç»†èƒæ£€æŸ¥ç‚¹ï¼Œé˜»ç¢æŠ—è‚¿ç˜¤å…ç–«â€”â€”Adam12CKO å°é¼ æ¨¡å‹ CD45- ç»†èƒçš„ scRNA-seq</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€immunityã€single-cellã€scRNA<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusClinical trials targeting cancer-associated fibroblasts (CAFs)â€”crucial pro-tumoral factors in cancerâ€”have almost all failed. This may be ascribed to their intrinsic functional plasticity and the opaque regulatory circuits underlying their heterogeneous phenotypes within tumors. We address these by developing a systematic screening approach for patient-derived fibroblasts using complementary CRISPR interference (CRISPRi) and activation (CRISPRa)-based perturb-seq. An anti-tumoral interferon (IFN)-I response-associated program is identified as the primary antagonism axis counteracting TGFÎ²-driven pro-tumoral myofibroblast activation. ADAM12 emerges as a molecular checkpoint mediating this relationship. Its ablation elicits IFN-I responsive programs, reconfigures myofibroblast population structures into progenitor-like states, revitalizes T cell-based immune responses, and induces tumor rejection across various murine models. Further combined with human genomics data analysis, our findings position ADAM12 as a potential target for fibroblasts, paving the way for actionable therapeutic interventions.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313761" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>GSE278983 å•ç»†èƒç­›é€‰é‰´å®šå‡ºADAM12ä¸ºæˆçº¤ç»´ç»†èƒæ£€æŸ¥ç‚¹ï¼Œé˜»ç¢æŠ—è‚¿ç˜¤å…ç–«â€”â€”å°é¼ KPCæ¨¡å‹çš„scRNA-seq</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€immunityã€single-cellã€scRNA<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusClinical trials targeting cancer-associated fibroblasts (CAFs)â€”crucial pro-tumoral factors in cancerâ€”have almost all failed. This may be ascribed to their intrinsic functional plasticity and the opaque regulatory circuits underlying their heterogeneous phenotypes within tumors. We address these by developing a systematic screening approach for patient-derived fibroblasts using complementary CRISPR interference (CRISPRi) and activation (CRISPRa)-based Perturb-seq . An anti-tumoral interferon (IFN)-I response-associated program is identified as the primary antagonism axis counteracting TGFÎ²-driven pro-tumoral myofibroblast activation. ADAM12 emerges as a molecular checkpoint mediating this relationship. Its ablation elicits IFN-I responsive programs, reconfigures myofibroblast population structures into progenitor-like states, revitalizes T cell-based immune responses, and induces tumor rejection across various murine models. Further combined with human genomics data analysis, our findings position ADAM12 as a potential target for fibroblasts, paving the way for actionable therapeutic interventions.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278983" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>GSE278980 å•ç»†èƒç­›é€‰é‰´å®šå‡º ADAM12 ä¸ºæˆçº¤ç»´ç»†èƒæ£€æŸ¥ç‚¹ï¼Œé˜»ç¢æŠ—è‚¿ç˜¤å…ç–«â€”â€”C57BL/6 å°é¼ æ¨¡å‹çš„ RNA æµ‹åº</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€immunityã€RNA-seqã€single-cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusClinical trials targeting cancer-associated fibroblasts (CAFs)â€”crucial pro-tumoral factors in cancerâ€”have almost all failed. This may be ascribed to their intrinsic functional plasticity and the opaque regulatory circuits underlying their heterogeneous phenotypes within tumors. We address these by developing a systematic screening approach for patient-derived fibroblasts using complementary CRISPR interference (CRISPRi) and activation (CRISPRa)-based Perturb-seq . An anti-tumoral interferon (IFN)-I response-associated program is identified as the primary antagonism axis counteracting TGFÎ²-driven pro-tumoral myofibroblast activation. ADAM12 emerges as a molecular checkpoint mediating this relationship. Its ablation elicits IFN-I responsive programs, reconfigures myofibroblast population structures into progenitor-like states, revitalizes T cell-based immune responses, and induces tumor rejection across various murine models. Further combined with human genomics data analysis, our findings position ADAM12 as a potential target for fibroblasts, paving the way for actionable therapeutic interventions.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278980" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>GSE278975 å•ç»†èƒç­›é€‰é‰´å®šå‡ºADAM12æ˜¯æˆçº¤ç»´ç»†èƒæ£€æŸ¥ç‚¹ï¼Œå¯é˜»ç¢æŠ—è‚¿ç˜¤å…ç–«â€”â€”å…±æ³¨å°„å°é¼ æ¨¡å‹çš„scRNA-seq</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€immunityã€single-cellã€scRNA<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusClinical trials targeting cancer-associated fibroblasts (CAFs)â€”crucial pro-tumoral factors in cancerâ€”have almost all failed. This may be ascribed to their intrinsic functional plasticity and the opaque regulatory circuits underlying their heterogeneous phenotypes within tumors. We address these by developing a systematic screening approach for patient-derived fibroblasts using complementary CRISPR interference (CRISPRi) and activation (CRISPRa)-based Perturb-seq . An anti-tumoral interferon (IFN)-I response-associated program is identified as the primary antagonism axis counteracting TGFÎ²-driven pro-tumoral myofibroblast activation. ADAM12 emerges as a molecular checkpoint mediating this relationship. Its ablation elicits IFN-I responsive programs, reconfigures myofibroblast population structures into progenitor-like states, revitalizes T cell-based immune responses, and induces tumor rejection across various murine models. Further combined with human genomics data analysis, our findings position ADAM12 as a potential target for fibroblasts, paving the way for actionable therapeutic interventions.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278975" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>GSE278974 å•ç»†èƒç­›é€‰é‰´å®šå‡º ADAM12 ä¸ºæˆçº¤ç»´ç»†èƒæ£€æŸ¥ç‚¹ï¼Œé˜»ç¢æŠ—è‚¿ç˜¤å…ç–«â€”â€”B16F10 è‚ºé»‘è‰²ç´ ç˜¤å°é¼ æ¨¡å‹çš„ RNA-seq</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€immunityã€RNA-seqã€single-cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusClinical trials targeting cancer-associated fibroblasts (CAFs)â€”crucial pro-tumoral factors in cancerâ€”have almost all failed. This may be ascribed to their intrinsic functional plasticity and the opaque regulatory circuits underlying their heterogeneous phenotypes within tumors. We address these by developing a systematic screening approach for patient-derived fibroblasts using complementary CRISPR interference (CRISPRi) and activation (CRISPRa)-based Perturb-seq . An anti-tumoral interferon (IFN)-I response-associated program is identified as the primary antagonism axis counteracting TGFÎ²-driven pro-tumoral myofibroblast activation. ADAM12 emerges as a molecular checkpoint mediating this relationship. Its ablation elicits IFN-I responsive programs, reconfigures myofibroblast population structures into progenitor-like states, revitalizes T cell-based immune responses, and induces tumor rejection across various murine models. Further combined with human genomics data analysis, our findings position ADAM12 as a potential target for fibroblasts, paving the way for actionable therapeutic interventions.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278974" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> â­ <strong>GSE311439 è„‚è´¨æ°§è‡ªç”±åŸºé˜²å¾¡é€šè·¯åŠå…¶è¡¨è§‚é—ä¼ æ§åˆ¶çš„é‰´å®š [ChIP-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šChIP-seqã€epigeneticã€pathway<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Francisco S Mesquita ; Laurence Abrami ; Romain Forey ; BÃ©atrice Kunz ; CharlÃ¨ne Raclot ; Lucie Bracq ; Danica Milovanovic ; Evarist Planet ; Olga Rosspopoff ; Filipe Martins ; Didier Trono ; Gisou van der GootSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensMembrane phospholipids are vulnerable to oxidative radicals, and uncontrolled lipid peroxidation affects cell viability. Cells have evolved quality control and defense mechanisms, of which the genetic regulation is not fully understood. Here, we identify what we have coined the Lipid Oxygen Radical Defense (LORD) pathway. It is epigenetically repressed by a complex comprising the KRAB-zinc finger protein ZNF354A, the scaffold protein KAP1/TRIM28, the histone methyltransferase SETDB1, and the transcriptional activator ATF2. Upon lipid peroxide accumulation, p38- and JNK-dependent phosphorylation of ATF2, KAP1/TRIM28, and ZNF354A leads to disassembly of the repressive complex, releasing ZNF354A from specific DNA loci and activating a network of protective genes, including NRF2 targets. The pathway affects the cellular sensitivity to oxidative stress and ferroptosis, revealing a previously uncharacterized layer of epigenetic control in lipid quality control and damage repair. This positions the LORD pathway as a promising therapeutic target for diseases linked to chronic inflammation, neurodegeneration and cancer.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311439" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> â­ <strong>GSE311436 è„‚è´¨æ°§è‡ªç”±åŸºé˜²å¾¡é€šè·¯åŠå…¶è¡¨è§‚é—ä¼ æ§åˆ¶çš„é‰´å®š [RNA-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šRNA-seqã€epigeneticã€pathway<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Francisco S Mesquita ; Evarist Planet ; Laurence Abrami ; Charlene Raclot ; Romain Forey ; Gisou van der GootSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensMembrane phospholipids are vulnerable to oxidative radicals, and uncontrolled lipid peroxidation affects cell viability. Cells have evolved quality control and defense mechanisms, of which the genetic regulation is not fully understood. Here, we identify what we have coined the Lipid Oxygen Radical Defense (LORD) pathway. It is epigenetically repressed by a complex comprising the KRAB-zinc finger protein ZNF354A, the scaffold protein KAP1/TRIM28, the histone methyltransferase SETDB1, and the transcriptional activator ATF2. Upon lipid peroxide accumulation, p38- and JNK-dependent phosphorylation of ATF2, KAP1/TRIM28, and ZNF354A leads to disassembly of the repressive complex, releasing ZNF354A from specific DNA loci and activating a network of protective genes, including NRF2 targets. The pathway affects the cellular sensitivity to oxidative stress and ferroptosis, revealing a previously uncharacterized layer of epigenetic control in lipid quality control and damage repair. This positions the LORD pathway as a promising therapeutic target for diseases linked to chronic inflammation, neurodegeneration and cancer.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311436" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> â­ <strong>GSE278990 å•ç»†èƒç­›é€‰å‘ç° ADAM12 æ˜¯æˆçº¤ç»´ç»†èƒæ£€æŸ¥ç‚¹ï¼Œå¯é˜»ç¢æŠ—è‚¿ç˜¤å…ç–«</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€immunityã€single-cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThis SuperSeries is composed of the SubSeries listed below.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278990" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>GSE293631 éœ¸æƒ EWSR1::ETS ç™ŒåŸºå› åœ¨å°¤æ–‡æ°è‚‰ç˜¤ä¸­å‡Œé©¾äºæ ¸å¿ƒè°ƒæ§å›è·¯æœºåˆ¶ä¹‹ä¸Š [ChIP-seq 2]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šregex:onco(logy|logist|gene|genic)ã€ChIP-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Sandrine Grossetete ; Sakina Zaidi ; Karine Laud-Duval ; Didier Surdez ; Olivier DelattreSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensEwing sarcoma is an aggressive bone tumor of adolescence characterized by a hallmark EWSR1::FLI1 fusion oncogene. This chimeric protein drives tumorigenesis by reshaping transcriptional and epigenetic landscapes. However, how it is transcriptionally regulated and whether additional master transcription factors (MTFs) form a core regulatory circuit (CRC) in Ewing sarcoma remain unclear. Here, using an extensive panel of Ewing sarcoma cell lines and primary tumors, we mapped super-enhancers and identified strong enrichment of GGAA microsatellites, confirming their specificity to Ewing sarcoma as compared to other pediatric cancers and normal tissues. Integrating transcriptomic, epigenetic, 3D chromatin conformation, and dependency data, we predicted a set of MTFs potentially comprising a CRC. However, functional validation demonstrated that these MTFs neither establish auto-regulatory loops nor confer proliferative dependencies typical of CRC s in other pediatric tumors. Instead, EWSR1::FLI1 emerged as an â€œhegemonicâ€ oncogene, regulating the expression of these MTFs without reciprocal regulation. Knockdown (KD) of EWSR1::FLI1 strongly reduced Ewing sarcoma cell proliferation and shifted H3K27ac profiles toward mesenchymal states, whereas silencing of individual or combined MTFs did not alter cell growth or EWSR1::FLI1 expression. These findings highlight the absence of a classical CRC in Ewing sarcoma and emphasize EWSR1::FLI1 as the dominant oncogene but also as a major vulnerability in this disease.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293631" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 58 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (4æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨4æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>ç ”ç©¶äººå‘˜å› åŸºå› ç»„å’ŒRNAæµ‹åºçš„å˜é©æ€§åº”ç”¨è€Œè·å¥–</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencingã€genome<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šPengfei Liu, Ph.D., is recognized for advancing RNA sequencing and genome-based diagnostics, improving rare disease diagnosis...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/researcher-awarded-for-transformative-use-of-genome-and-rna-sequencing/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>åˆ©ç”¨RNAæµ‹åºå’Œå› æœæ¨¡å‹å°†åŸºå› ä¸æ€§çŠ¶è”ç³»èµ·æ¥</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencing<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šBy combining genetic effect sizes with RNA sequencing based perturbation data, researchers map causal pathways from genes to cellular programs and human traits...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/linking-genes-to-traits-using-rna-sequencing-and-causal-modeling/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>å¤§éº»åŒ–åˆç‰©å±•ç°å‡ºå¯¹æŠ—åµå·¢ç™Œçš„æ„å¤–åŠŸæ•ˆ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šScientists have discovered that key compounds from cannabisâ€”CBD and THCâ€”show surprisingly strong effects against ovarian cancer cells. Used together, they slow cell growth, reduce colony formation, and may even block the cancerâ€™s ability to spread. Even more promising, the treatment caused minimal harm to healthy cells and appears to work by restoring a disrupted signaling pathway that fuels tumor growth.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/12/251215025315.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>ç„¦è™‘å’Œå¤±çœ ä¸å…³é”®å…ç–«ç»†èƒæ•°é‡æ€¥å‰§ä¸‹é™æœ‰å…³</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmune<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šNatural killer cells act as the immune systemâ€™s rapid-response team, but the stress of anxiety and insomnia may be quietly thinning their ranks. A study of young women in Saudi Arabia found that both conditions were linked to significantly fewer NK cellsâ€”especially the circulating types responsible for destroying infected or abnormal cells. As anxiety severity increased, NK cell levels dropped even further, suggesting a stress-driven weakening of immune defenses.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/12/251214100924.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>cancer</td>
<td>18</td>
</tr>
<tr>
<td>RNA-seq</td>
<td>10</td>
</tr>
<tr>
<td>tumor</td>
<td>9</td>
</tr>
<tr>
<td>single-cell</td>
<td>9</td>
</tr>
<tr>
<td>ChIP-seq</td>
<td>7</td>
</tr>
<tr>
<td>immunity</td>
<td>7</td>
</tr>
<tr>
<td>sequencing</td>
<td>6</td>
</tr>
<tr>
<td>scRNA</td>
<td>5</td>
</tr>
<tr>
<td>immune</td>
<td>5</td>
</tr>
<tr>
<td>pathway</td>
<td>4</td>
</tr>
<tr>
<td>regex:onco(logy</td>
<td>logist</td>
</tr>
<tr>
<td>Neuronal</td>
<td>4</td>
</tr>
<tr>
<td>epigenetic</td>
<td>3</td>
</tr>
<tr>
<td>ATAC-seq</td>
<td>3</td>
</tr>
<tr>
<td>Alzheimer</td>
<td>3</td>
</tr>
<tr>
<td>metabolic</td>
<td>2</td>
</tr>
<tr>
<td>RNAseq</td>
<td>2</td>
</tr>
<tr>
<td>genome</td>
<td>1</td>
</tr>
<tr>
<td>spatially</td>
<td>1</td>
</tr>
<tr>
<td>KRAS</td>
<td>1</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (58æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293630" target="_blank" rel="noopener noreferrer">GSE293630 éœ¸æƒ EWSR1::ETS ç™ŒåŸºå› åœ¨å°¤æ–‡æ°è‚‰ç˜¤ä¸­å‡Œé©¾äºæ ¸å¿ƒè°ƒæ§å›è·¯æœºåˆ¶ä¹‹ä¸Š [ChIP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293629" target="_blank" rel="noopener noreferrer">GSE293629 éœ¸æƒ EWSR1::ETS ç™ŒåŸºå› åœ¨å°¤æ–‡æ°è‚‰ç˜¤ä¸­å‡Œé©¾äºæ ¸å¿ƒè°ƒæ§å›è·¯æœºåˆ¶ä¹‹ä¸Š [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292538" target="_blank" rel="noopener noreferrer">GSE292538 KRASä¾èµ–æ€§å†…çš®ç»†èƒä»£è°¢é‡ç¼–ç¨‹ä½œä¸ºè„‘åŠ¨é™è„‰ç•¸å½¢çš„æ²»ç–—å¼±ç‚¹</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE255078" target="_blank" rel="noopener noreferrer">GSE255078 æ–­å¥¶åå–‚é£Ÿå«åŠä¹³ç³–ã€è‘¡è„ç³–æˆ–ä¹³ç³–é¥®é£Ÿçš„å°é¼ è¿‘ç«¯å°è‚ åˆ®å–ç‰©çš„ RNA æµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312888" target="_blank" rel="noopener noreferrer">GSE312888 è¡¨è§‚è½¬å½•ç»„ç¼–è¾‘ç­›é€‰é‰´å®šç™Œç—‡ä¸­çš„åŠŸèƒ½æ€§ m6A ä½ç‚¹ [RNA-Seq 22Rv1 M3 å†™å…¥]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300690" target="_blank" rel="noopener noreferrer">GSE300690 ç¥ç»å…ƒ Idol åŸºå› ç¼ºå¤±é€šè¿‡ APOE å—ä½“æ”¹å–„é˜¿å°”èŒ¨æµ·é»˜ç—…ç›¸å…³ç—…ç†</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298088" target="_blank" rel="noopener noreferrer">GSE298088 äººç±»åµå·¢é€æ˜ç»†èƒç™ŒPDXè‚¿ç˜¤çš„RNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292092" target="_blank" rel="noopener noreferrer">GSE292092 é”™é…ä¿®å¤ç¼ºé™·é©±åŠ¨æ¶æ€§è¿›å±•å¹¶æ”¹å˜èƒ¶è´¨æ¯ç»†èƒç˜¤çš„è‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280897" target="_blank" rel="noopener noreferrer">GSE280897 PUF60ä»‹å¯¼çš„å‰ªæ¥æ˜¯ä¸‰é˜´æ€§ä¹³è…ºç™Œçš„å…³é”®é©±åŠ¨å› ç´ [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE261507" target="_blank" rel="noopener noreferrer">GSE261507 å…·æœ‰æ—¶é—´åˆ†è¾¨ç‡çš„æˆå¹´C57BL/6å°é¼ è˜æ£’çŠ¶ç»†èƒæŸä¼¤åè‚ºéƒ¨å…ç–«ç»†èƒçš„å•ç»†èƒè½¬å½•ç»„åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE255794" target="_blank" rel="noopener noreferrer">GSE255794 è¡¨è§‚è½¬å½•ç»„ç¼–è¾‘ç­›é€‰é‰´å®šç™Œç—‡ä¸­çš„åŠŸèƒ½æ€§ m6A ä½ç‚¹ [ATAC-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE255792" target="_blank" rel="noopener noreferrer">GSE255792 è¡¨è§‚è½¬å½•ç»„ç¼–è¾‘ç­›é€‰é‰´å®šç™Œç—‡ä¸­çš„åŠŸèƒ½æ€§ m6A ä½ç‚¹ [ChIP-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313336" target="_blank" rel="noopener noreferrer">GSE313336 CALD1/IGF2BP1 å¤åˆç‰©é€šè¿‡ä»¥ mâ¶A ä¾èµ–çš„æ–¹å¼å¢å¼º RFC4 mRNA çš„ç¨³å®šæ€§æ¥ä»‹å¯¼è†€èƒ±ç™Œçš„é¡ºé“‚è€è¯æ€§ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312993" target="_blank" rel="noopener noreferrer">GSE312993 FlncKO-C2C12 è‚Œæºæ€§åˆ†åŒ–è¿‡ç¨‹ä¸­çš„è½¬å½•ç»„åˆ†æï¼ˆæ‰¹é‡ RNA æµ‹åºï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312903" target="_blank" rel="noopener noreferrer">GSE312903 Connectome-seqï¼šé€šè¿‡æ¡å½¢ç æµ‹åºæŠ€æœ¯ä»¥å•çªè§¦åˆ†è¾¨ç‡è¿›è¡Œé«˜é€šé‡ç¥ç»å…ƒè¿æ¥å›¾è°±ç»˜åˆ¶[snRNA-seq, ssRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307955" target="_blank" rel="noopener noreferrer">GSE307955 H526å°ç»†èƒè‚ºç™Œç»†èƒä¸­PAX5çš„ChIP-seqåˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301438" target="_blank" rel="noopener noreferrer">GSE301438 TopBP1 é€šè¿‡ PU.1 å’Œ IRF8 æ§åˆ¶ä¼ ç»Ÿæ ‘çªçŠ¶ç»†èƒå‘è‚²å’Œ Flt3L é©±åŠ¨çš„ cDC1 åˆ†åŒ– [ChIP-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE271510" target="_blank" rel="noopener noreferrer">GSE271510 å°é¼ KPCèƒ°è…ºè‚¿ç˜¤çš„å•ç»†èƒRNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE271509" target="_blank" rel="noopener noreferrer">GSE271509 å°é¼ KPCèƒ°è…ºè‚¿ç˜¤çš„å•ç»†èƒATACæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312168" target="_blank" rel="noopener noreferrer">GSE312168 ç»„ç»‡æŸä¼¤ç ”ç©¶ä¸­è½¬å½•ç»„å’Œä»£è°¢ç»„å˜åŒ–çš„ç©ºé—´åˆ†è¾¨æ•´åˆåˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298302" target="_blank" rel="noopener noreferrer">GSE298302 è¥¿è¾¾ç±³å¾·å’Œå¡åˆ©å°¼ç´¢é€šè¿‡æŠ‘åˆ¶ Survivin å’Œ PI3K/AKT é€šè·¯ï¼Œåœ¨é«˜çº§åˆ« B ç»†èƒæ·‹å·´ç˜¤ä¸­å‘æŒ¥åŒé‡è¡¨è§‚é—ä¼ å’Œæ ¸è¾“å‡ºæŠ‘åˆ¶ä½œç”¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE286170" target="_blank" rel="noopener noreferrer">GSE286170 GABAèƒ½ç¥ç»å…ƒåœ¨é©±åŠ¨è„†æ€§XæŸ“è‰²ä½“å‰çªå˜æºå¸¦è€…ç›¸å…³çš„CGGé‡å¤æ¯’æ€§ä¸­èµ·å…³é”®ä½œç”¨[scRNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE256000" target="_blank" rel="noopener noreferrer">GSE256000 åŸå‘æ€§è‚¾å°ç®¡å’Œé€æ˜ç»†èƒè‚¾ç»†èƒç™Œç»†èƒä¸­å¼€æ”¾æŸ“è‰²è´¨ã€HIF ç»“åˆå’Œ mRNA è¡¨è¾¾åˆ†æ [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE255998" target="_blank" rel="noopener noreferrer">GSE255998 åŸå‘æ€§è‚¾å°ç®¡å’Œ ccRCC ç»†èƒä¸­çš„å¼€æ”¾æŸ“è‰²è´¨ã€HIF ç»“åˆå’Œ mRNA è¡¨è¾¾åˆ†æ [ATAC-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE255997" target="_blank" rel="noopener noreferrer">GSE255997 åŸå‘æ€§è‚¾å°ç®¡å’Œ ccRCC ç»†èƒä¸­å¼€æ”¾æŸ“è‰²è´¨ã€HIF ç»“åˆå’Œ mRNA è¡¨è¾¾åˆ†æ [ChIP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313775" target="_blank" rel="noopener noreferrer">GSE313775 å­å®«å†…è†œå¼‚ä½ç—‡æ‚£è€…å’Œå¯¹ç…§ç»„çš„å¾ªç¯ Th1ã€Th1/17 å’Œ Th17 ç»†èƒ RNA æµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313636" target="_blank" rel="noopener noreferrer">GSE313636 å¯¹æœªæ„ŸæŸ“æˆ–å‡ç»“æ ¸è€¶å°”æ£®èŒæ„ŸæŸ“çš„å›è‚ è¿›è¡Œç©ºé—´è½¬å½•ç»„åˆ†æï¼Œæ­ç¤ºäº†ä¸€ç§æ–°çš„è‚ ç»†èƒè½¬å½•çŠ¶æ€</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313324" target="_blank" rel="noopener noreferrer">GSE313324 PUF60ä»‹å¯¼çš„å‰ªæ¥æ˜¯ä¸‰é˜´æ€§ä¹³è…ºç™Œçš„å…³é”®é©±åŠ¨å› ç´ [CRISPR]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313289" target="_blank" rel="noopener noreferrer">GSE313289 é€šè¿‡åŸºå› è¡¨è¾¾äº†è§£å¤´é¢ˆéƒ¨é³çŠ¶ç»†èƒç™Œçš„è‚¿ç˜¤å¼‚è´¨æ€§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313117" target="_blank" rel="noopener noreferrer">GSE313117 åŸºäºåŸºå› è¡¨è¾¾çš„ç™Œç—‡åˆ†å­åˆ†å‹è·¨å¹³å°æ¯”è¾ƒæ­ç¤ºäº†ä¸å¤–æ˜¾å­æ•è·æ–¹æ³•çš„å·®å¼‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312890" target="_blank" rel="noopener noreferrer">GSE312890 è¡¨è§‚è½¬å½•ç»„ç¼–è¾‘ç­›é€‰é‰´å®šç™Œç—‡ä¸­çš„åŠŸèƒ½æ€§ m6A ä½ç‚¹ [CRISPR screen_H358]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309818" target="_blank" rel="noopener noreferrer">GSE309818 ç¥ç»åµ´ç»†èƒè¡ç”Ÿçš„ DKK1 è°ƒèŠ‚ç¬¬äºŒå¿ƒåœºä¸­çš„ Wnt ä¿¡å·ä¼ å¯¼ï¼Œä»è€Œåè°ƒå¿ƒè„æµå‡ºé“å‘è‚²ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305625" target="_blank" rel="noopener noreferrer">GSE305625 ä¾›ä½“åŒ¹é…è¡€æµ†å’Œè„‘è„Šæ¶²ä¸­å¤šmiRNAæ¨¡å‹ä½œä¸ºé˜¿å°”èŒ¨æµ·é»˜ç—…é¢„æµ‹å€™é€‰ç”Ÿç‰©æ ‡å¿—ç‰©çš„æ¯”è¾ƒ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297746" target="_blank" rel="noopener noreferrer">GSE297746 è‡ªç”±æ¼‚æµ®çš„é•¿æœŸè¡€ç®¡åŒ–é—´å……è´¨ç±»å™¨å®˜ [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297680" target="_blank" rel="noopener noreferrer">GSE297680 è‡ªç”±æ¼‚æµ®çš„é•¿æœŸè¡€ç®¡åŒ–é—´å……è´¨ç±»å™¨å®˜ [scRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295765" target="_blank" rel="noopener noreferrer">GSE295765 ç¯çŠ¶ ZBTB44 ç¼–ç çš„ ZBTB44-342aa é€šè¿‡æŠ‘åˆ¶ cGAS-STING é€šè·¯å‡è½»äººä¸»åŠ¨è„‰ç“£é—´è´¨ç»†èƒçš„æˆéª¨åˆ†åŒ–</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280899" target="_blank" rel="noopener noreferrer">GSE280899 PUF60ä»‹å¯¼çš„å‰ªæ¥æ˜¯ä¸‰é˜´æ€§ä¹³è…ºç™Œçš„å…³é”®é©±åŠ¨å› ç´ </a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280898" target="_blank" rel="noopener noreferrer">GSE280898 PUF60ä»‹å¯¼çš„å‰ªæ¥æ˜¯ä¸‰é˜´æ€§ä¹³è…ºç™Œçš„å…³é”®é©±åŠ¨å› ç´ [eCLIP]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE268609" target="_blank" rel="noopener noreferrer">GSE268609 äººç±»æµ·é©¬ç¥ç»å‘ç”Ÿä¸æˆå¹´ã€è¡°è€å’Œé˜¿å°”èŒ¨æµ·é»˜ç—…çš„å…³ç³»è·¯çº¿å›¾</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE243490" target="_blank" rel="noopener noreferrer">GSE243490 äººç±»å—œé…¸æ€§ç²’ç»†èƒ1å‹å’Œ2å‹çš„å…ç–«æåŒ–</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE243369" target="_blank" rel="noopener noreferrer">GSE243369 å°é¼ å—œé…¸æ€§ç²’ç»†èƒ1å‹å’Œ2å‹çš„å…ç–«æåŒ–</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE242447" target="_blank" rel="noopener noreferrer">GSE242447 è¡¨è§‚è½¬å½•ç»„ç¼–è¾‘ç­›é€‰é‰´å®šå‡ºç™Œç—‡ä¸­çš„åŠŸèƒ½æ€§ m6A ä½ç‚¹</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE242446" target="_blank" rel="noopener noreferrer">GSE242446 è¡¨è§‚è½¬å½•ç»„ç¼–è¾‘ç­›é€‰é‰´å®šç™Œç—‡ä¸­çš„åŠŸèƒ½æ€§ m6A ä½ç‚¹ [CRISPR screen_22Rv1]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE242444" target="_blank" rel="noopener noreferrer">GSE242444 è¡¨è§‚è½¬å½•ç»„ç¼–è¾‘ç­›é€‰é‰´å®šç™Œç—‡ä¸­çš„åŠŸèƒ½æ€§ m6A ä½ç‚¹ [RNA-Seq_shKD]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313838" target="_blank" rel="noopener noreferrer">GSE313838 é›„æ¿€ç´ å—ä½“é˜´æ€§å‰åˆ—è…ºç™Œæ˜“å—SWI/SNFé¶å‘é™è§£åˆ†å­çš„å½±å“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313525" target="_blank" rel="noopener noreferrer">GSE313525 TAK1 æ˜¯æ¨ªçº¹è‚Œè‚‰ç˜¤ä¸­è‡´ç™Œä¿¡å·ä¼ å¯¼å’Œåˆ†åŒ–é˜»æ»çš„å…³é”®è°ƒèŠ‚å› å­</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313497" target="_blank" rel="noopener noreferrer">GSE313497 æ€¥æ€§ç¡çœ å‰¥å¤ºå¯¹å°é¼ æµ·é©¬å’Œå‰é¢å¶çš®å±‚éç¥ç»å…ƒç»†èƒè½¬å½•ç»„ç‰¹å¾çš„ç»†èƒç‰¹å¼‚æ€§å½±å“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313438" target="_blank" rel="noopener noreferrer">GSE313438 æ·«ç¾Šè—¿è‹·é€šè¿‡ä¿ƒè¿›TFEBä¾èµ–æ€§çº¿ç²’ä½“æ¸…é™¤å’Œä»£è°¢é‡ç¼–ç¨‹æ¥ç¼“è§£è¿åŠ¨å¼•èµ·çš„ç–²åŠ³</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313307" target="_blank" rel="noopener noreferrer">GSE313307 ç³»ç»Ÿæ€§æ„ŸæŸ“æ”¹å˜é˜¿å°”èŒ¨æµ·é»˜ç—…æ‚£è€…çš„çš®è´¨è½¬å½•ç‰¹å¾</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312982" target="_blank" rel="noopener noreferrer">GSE312982 äººç±»éª¨é«“è„‚è‚ªç»†èƒé€šè¿‡è„‚è´¨ä»‹å¯¼çš„è¡€ç®¡ç”Ÿæˆç´ æ ·è›‹ç™½4è¯±å¯¼ä¿ƒè¿›å‰åˆ—è…ºç™Œéª¨è½¬ç§»è¿›å±•</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308383" target="_blank" rel="noopener noreferrer">GSE308383 å°é¼ è‚ ç¥ç»ç³»ç»Ÿçš„å•æ ¸è½¬å½•ç»„åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307220" target="_blank" rel="noopener noreferrer">GSE307220 Dgat1 é€šè¿‡è§£æ¯’é›„æ¿€ç´ å—ä½“ä¿¡å·é€šè·¯ä¿ƒè¿›æŠ—è‚¿ç˜¤ CD8+ T ç»†èƒååº”</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301451" target="_blank" rel="noopener noreferrer">GSE301451 ç¥ç»å…ƒå¶åƒç¼ºå¤±å¯æ”¹å–„æ·€ç²‰æ ·è›‹ç™½ç—…ç†</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296719" target="_blank" rel="noopener noreferrer">GSE296719 é“‚(II)é…åˆç‰©æŠ‘åˆ¶ç™Œå¹²ç»†èƒè‡ªæˆ‘æ›´æ–°å¯æŠ‘åˆ¶èƒƒè‚ é“ç™Œè½¬ç§»</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295408" target="_blank" rel="noopener noreferrer">GSE295408 é¶å‘è¡€æ¸…ç´ é©±åŠ¨çš„ç»„è›‹ç™½è¡€æ¸…ç´ åŒ–å¯æŠ‘åˆ¶NEPCçš„è°±ç³»å¯å¡‘æ€§å’Œè¿›å±•</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289577" target="_blank" rel="noopener noreferrer">GSE289577 NR5A2 çš„å‰é¦ˆè°ƒæ§ç¯è·¯ç¡®ä¿æ¤å…¥å‰å‘è‚²è¿‡ç¨‹ä¸­åŸºå› çš„ç¨³å¥æ¿€æ´» [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289573" target="_blank" rel="noopener noreferrer">GSE289573 NR5A2 çš„å‰é¦ˆè°ƒæ§ç¯è·¯ç¡®ä¿æ¤å…¥å‰å‘è‚²è¿‡ç¨‹ä¸­åŸºå› çš„ç¨³å¥æ¿€æ´» [ATAC-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE124850" target="_blank" rel="noopener noreferrer">GSE124850 ç¯çŠ¶RNAåœ¨è‚ç»†èƒç™Œè‚¿ç˜¤åŠè‚¿ç˜¤å‘¨å›´ç»„ç»‡ä¸­çš„è¡¨è¾¾åˆ†æ</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-12-16 21:39</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>